I am blogging live from the east wing of McCormick Place here on Chicago’s lakefront. The room is large–I estimate there are about 1400 myeloma docs, researchers and clinicians here. Dr. Vij is speaking about the new 004 carfilzomib study. This particular event is chaired by Dr. Chanan-Khan, representing Roswell Park Cancer Institute, and Dr. Kumar from Mayo Clinic.
No new news–Dr. Vij is reviewing the clinical trial results I have covered the past two days. Still, a high dose response rate of 55% in refractory patients is impressive–and hopeful!
More later, including info about the “new improved” Revlimid–pomalidomide. Feel good and keep smiling! Pat